Retigabine dihydrochloride

CAS No. 150812-13-8

Retigabine dihydrochloride ( Ezogabine,D-23129 )

Catalog No. M22738 CAS No. 150812-13-8

Retigabine dihydrochloride is an anticonvulsant used as an adjunctive treatment for partial epilepsies in treatment-experienced adult patients.?The mechanism of action involves opening of neuronal K(V)7.2-7.5 (formerly KCNQ2-5) voltage-activated K(+) channels.In differentiated PC12 cells, retigabine enhanced a linopirdine-sensitive current.?

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 35 In Stock
50MG Get Quote In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Retigabine dihydrochloride
  • Note
    Research use only, not for human use.
  • Brief Description
    Retigabine dihydrochloride is an anticonvulsant used as an adjunctive treatment for partial epilepsies in treatment-experienced adult patients.?The mechanism of action involves opening of neuronal K(V)7.2-7.5 (formerly KCNQ2-5) voltage-activated K(+) channels.In differentiated PC12 cells, retigabine enhanced a linopirdine-sensitive current.?
  • Description
    Retigabine dihydrochloride is an anticonvulsant used as an adjunctive treatment for partial epilepsies in treatment-experienced adult patients.?The mechanism of action involves opening of neuronal K(V)7.2-7.5 (formerly KCNQ2-5) voltage-activated K(+) channels.In differentiated PC12 cells, retigabine enhanced a linopirdine-sensitive current.?The effect of retigabine was associated with a slowing of M-like tail current deactivation in these cells.?Retigabine (0.1 to 10 microM) induced a potassium current and hyperpolarized CHO cells expressing KCNQ2/Q3 cells but not in wild-type cells.?Retigabine-induced currents in CHO-KCNQ2/Q3 cells were inhibited by 60.6 +/- 11% (n = 4) by the KCNQ2/Q3 blocker, linopirdine (10 microM), and 82.7 +/- 5.4% (n = 4) by BaCl(2) (10 mM).?The mechanism by which retigabine enhanced KCNQ2/Q3 currents involved large, drug-induced, leftward shifts in the voltage dependence of channel activation (-33.1 +/- 2.6 mV, n = 4, by 10 microM retigabine).?Retigabine shifted the voltage dependence of channel activation with an EC(50) value of 1.6 +/- 0.3 microM (slope factor was 1.2 +/- 0.1, n = 4 to 5 cells per concentration).?Retigabine (0.1 to 10 microM) also slowed the rate of channel deactivation, predominantly by increasing the contribution of a slowly deactivating tail current component.?
  • Synonyms
    Ezogabine,D-23129
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    Potassium Channel
  • Recptor
    KCNQ3/5;KCNQ2/Q3;KCQN4
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    150812-13-8
  • Formula Weight
    376.25
  • Molecular Formula
    C16H20Cl2FN3O2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    Cl.Cl.CCOC(=O)Nc1ccc(NCc2ccc(F)cc2)cc1N
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Wickenden A D , Yu W , Zou A , et al. Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels.[J]. Molecular Pharmacology, 2000, 58(3):591-600.
molnova catalog
related products
  • Amsacrine

    Amsacrine (mAMSA) an antineoplastic agent which can intercalate into the DNA of tumor cells.

  • VU591 hydrochloride

    VU591 hydrochloride is a selective renal outer medullary potassium channel (Kir1.1, ROMK) antagonist (IC50:0.24 μM).?Thought to block the intracellular pore of the Kir1.1 channel.?Exhibits no effect on Kir7.1 at concentrations up to 10 μM;?does not inhibit Kir2.1, Kir2.3 or Kir4.1.?

  • AUT1

    AUT1 (AUT-1) is a novel specific modulator of Kv3 channels (EC50: 4.7 and 4.9 uM for Kv3.1b and Kv3.2a).